Your vet just said the word “Numelvi” and you're home looking it up. Fair. It's new. Numelvi is the brand name for atinvicitinib, a second-generation JAK1 inhibitor that the FDA approved in February 2026 for allergic dermatitis and atopic dermatitis in dogs six months and older. If you've been through the allergy-medication conversation before, you already know the first-generation version: Apoquel, the oclacitinib tablet that's been the daily standard since 2013.
Apoquel works. Twelve years of post-market data confirm that. But it also blocks more than it needs to. When Apoquel targets JAK1 to shut down the itch signal, it catches JAK3 and some JAK2 on the way through. Those off-target effects are part of the reason vets watch neutrophil counts, flag recurring infections, and schedule periodic bloodwork. Numelvi was built to do the same job with a narrower aim.
What JAK1 selectivity actually means for your dog
JAK enzymes are a family of four: JAK1, JAK2, JAK3, and TYK2. The one that matters for allergic itch is JAK1. It sits in the signaling pathway between the allergen trigger and the scratching. Block JAK1, and the itch signal doesn't reach the brain.
Apoquel blocks JAK1, but its selectivity ratio isn't tight. It inhibits JAK3 nearly as strongly, and JAK2 to a degree. JAK2 and JAK3 are involved in red blood cell production and broader immune function. That's the tradeoff that shows up in the bloodwork.
Atinvicitinib was engineered for roughly ten times greater selectivity for JAK1 over JAK2, JAK3, and TYK2. Merck Animal Health, the manufacturer, describes this as “second-generation” JAK inhibition. The clinical reasoning is straightforward: if you can block the itch pathway without suppressing the immune pathways as deeply, the side-effect profile should be narrower. Whether that holds up across years of real-world use is the question the post-market data hasn't answered yet. The selectivity numbers come from bench assays. The side-effect profile comes from dogs in clinics. Those are related but not the same thing.
Who Numelvi is for
The FDA label covers dogs six months and older with allergic dermatitis, including atopic dermatitis. That age cutoff matters. Apoquel's label starts at twelve months. Zenrelia's starts at twelve months. Numelvi is the only JAK inhibitor your vet can prescribe for a dog between six and twelve months old.
If you have a nine-month-old puppy scratching through the night, and your vet has ruled out food allergy and parasites, the allergy-medication conversation used to land on Cytopoint (the injection, no age restriction) or antihistamines. Now Numelvi is in the daily-tablet column for that age range. That's a real clinical expansion, not a marketing distinction.
For adult dogs already stable on Apoquel, the case for switching isn't automatic. Twelve years of Apoquel post-market data is a known quantity. Your vet knows what Apoquel does in your dog's body because they've been watching the bloodwork for months or years. Switching to Numelvi means starting that observation window over. The scenario where the switch makes clinical sense is when Apoquel is causing problems: declining neutrophil counts, recurring skin infections, liver enzyme shifts that your vet attributes to the medication.
Side effects from the FDA field study
The FDA's Freedom of Information summary for atinvicitinib lists the adverse events reported during the pivotal field study. The most common were gastrointestinal: vomiting, decreased appetite, and soft stool. These are consistent with the JAK inhibitor class. Apoquel and Zenrelia carry similar GI findings in their early datasets.
The findings that shape the monitoring conversation sit in two categories: blood counts and liver values. Leukopenia, a drop in white blood cell count with neutrophils taking the biggest hit, appeared in the study population. Liver enzyme shifts were also flagged. Neither finding is unique to Numelvi. Apoquel's decade of data shows similar patterns. What's different is the depth of the safety record: the Numelvi field study evaluated safety over 28 days. That's the window the FDA reviewed. Dogs who take Numelvi for six months, a year, three years, are generating the post-market data right now. Your dog is part of that data.
The practical takeaway: the side effects aren't surprising for the drug class, but the long-term safety profile is an open question. Your vet will want closer monitoring intervals than they'd set for a dog that's been stable on Apoquel for two years. That's not a red flag. It's the standard of care for a new medication with a short real-world record.
Where to buy Numelvi and what it costs
Numelvi requires a prescription. Your vet writes it after evaluating your dog's allergy history, current medications, and baseline bloodwork. You can fill it at the clinic pharmacy, through Chewy's vet-verified pharmacy (three SKUs: 4.8 mg, 21.6 mg, 31.6 mg), or through Amazon's pet pharmacy. All three require prescription verification before dispensing.
Early pricing puts Numelvi in a range similar to Apoquel: roughly $2 to $4 per day depending on the dog's weight, which works out to $60 to $120 per month. Pricing will shift as distribution matures. Ask your clinic for the per-month cost at your dog's specific dose weight before starting. Factor in the bloodwork costs: a CBC (complete blood count, the red-and-white-cell panel) runs $50 to $150 at most clinics, and your vet will want one before starting and again at whatever interval the clinical picture warrants.
How Numelvi fits alongside the other options
The allergy-medication landscape for dogs now has five players: Apoquel, Zenrelia, Numelvi (all daily oral JAK inhibitors), Cytopoint (a monthly or bimonthly injection targeting IL-31), and Befrena (a newer injection targeting IL-31 from a different angle). The full comparison of all five medications covers how each works, what each costs, and the decision framework for choosing between them. The short version here: Numelvi occupies the same daily-tablet category as Apoquel and Zenrelia but offers tighter JAK1 selectivity and the youngest age label. If your vet is suggesting Numelvi, the conversation is usually about whether the selectivity advantage outweighs the shorter safety record for your specific dog.
I spent years handing clients the same three allergy-medication options. Now there are five, and the conversation has gotten longer, but it should have always been this long. The allergy drug decision is not a prescription and a wave goodbye. It's a bloodwork commitment, a monitoring schedule, and a plan B. The clinics that rush it pay for it later in confused phone calls and missed rechecks. The ones that take the extra ten minutes on the front end don't.
What to ask your vet before starting Numelvi
Three questions that cut to what matters.
Why Numelvi over Apoquel for my dog? The answer should be specific to your dog's history. If the vet is suggesting Numelvi because of bloodwork trends on Apoquel, ask which values are moving and in what direction. If it's for a puppy under twelve months, the answer is straightforward: it's the only daily JAK inhibitor labeled for that age.
What's the monitoring schedule? Expect a CBC before starting and at a closer interval than you'd see for established Apoquel patients. Every three months for the first year is reasonable. Ask what specifically the vet will be watching for. The answer should include neutrophils and liver enzymes.
What do we do if it doesn't work? The vet should have a plan B before you start plan A. If Numelvi doesn't control the itch at the prescribed dose within two to four weeks, or if the bloodwork shifts in a direction the vet doesn't like, what's the next step? Cytopoint injection? Back to Apoquel? Combination protocol? That conversation is easier to have before you're three weeks in and frustrated.
What to track at home
The value of a new medication with a short track record is directly proportional to how well you observe what it does. Track four things.
Itch level. Your vet may give you a scale (the pruritus Visual Analog Scale runs 0 to 10). If not, pick your own consistent benchmark: how many times the dog scratches during dinner, whether the belly is pink or red, whether the paws are stained. Log it daily for the first two weeks, then weekly.
Stomach and gut signs. Vomiting, soft stool, skipped meals. Date and time. The FDA study flagged gastrointestinal (GI) events as the most common adverse finding. If they appear, your vet needs to know when they started relative to the first dose.
Appetite and energy. A one-line note after each dose: ate normally, skipped breakfast, slower on the walk. These entries turn into patterns across weeks. The medication side-effect log gives you a structured format for tracking exactly this.
Weight. Monthly weigh-ins. Weight shifts on any new medication are information, especially in the first three months. A five-pound change in either direction gets mentioned at the recheck.
Veta's health passport captures medication responses alongside lab results, vet visits, and weight history. Log the dose from your phone, voice-note what you observed this morning, and the next time your vet asks what happened between visits, the record is already there.
Questions about Numelvi for dogs
Is Numelvi safe for puppies?
Numelvi is labeled for dogs six months and older. That's the youngest approval of any JAK inhibitor for atopic dermatitis. Apoquel's label starts at twelve months. Zenrelia's starts at twelve months. If your puppy is between six and twelve months old and scratching through the night, Numelvi is the only JAK inhibitor your vet can legally prescribe. The field study included dogs as young as six months, but the safety window was 28 days. Long-term data in puppies doesn't exist yet. Your vet will weigh the itch severity against that data gap.
How is Numelvi different from Apoquel if they're both JAK inhibitors?
Both target JAK1, the enzyme in the itch-signal pathway. The difference is selectivity. Apoquel blocks JAK1 but also catches JAK3 and some JAK2 activity. Those off-target effects are what drive the immune-suppression side of the ledger: the neutrophil dips, the infection susceptibility. Numelvi was designed to hit JAK1 with roughly ten times more selectivity over JAK2, JAK3, and TYK2. Tighter aim at the itch pathway, less collateral on the immune system. Whether that translates to fewer real-world side effects is the question the post-market data will answer over the next few years.
What does Numelvi cost compared to other allergy medications?
Early pricing puts Numelvi in a range similar to Apoquel, roughly $2 to $4 per day depending on your dog's weight. Chewy lists three SKUs (4.8 mg, 21.6 mg, 31.6 mg) and Amazon carries the 31.6 mg. Pricing will shift as distribution matures and more pharmacies stock it. Ask your clinic for the per-month cost at your dog's dose weight before committing. If you're comparing total cost, factor in the bloodwork: JAK inhibitors need periodic blood count monitoring regardless of the brand.
Can my dog take Numelvi with heartworm or flea preventives?
The FDA field study didn't report interactions with common heartworm or flea and tick preventives at standard doses. The combination to approach carefully is Numelvi with other immunosuppressive medications: corticosteroids at immunosuppressive doses or cyclosporine. Stacking immune suppression raises infection risk. If your dog is currently on prednisone and your vet is bridging to Numelvi, the overlap period and taper schedule matter. Don't adjust either drug on your own. Call the clinic and ask.
Does Numelvi require bloodwork monitoring?
Yes. Same principle as Apoquel. A CBC (the red-and-white-cell count panel) before starting and again at the interval your vet sets. Neutrophils are the line to watch because JAK inhibition can lower white blood cell counts. A chemistry panel checking liver values is also warranted because the FDA's Freedom of Information summary flagged liver-related findings in the field study. Your vet may run labs more frequently in the first six months than they would for a dog that's been stable on Apoquel for years. New drug, shorter safety record, closer monitoring.
Where can I buy Numelvi?
Numelvi requires a prescription. Your vet writes it, and you can fill it at the clinic pharmacy, through Chewy's vet-verified pharmacy, or through Amazon's pet pharmacy. All three require prescription verification before dispensing. You can't buy it over the counter. If you find it listed without a prescription requirement, that's not a legitimate source.
Should I switch my dog from Apoquel to Numelvi?
That depends on how your dog is doing right now. If the itch is controlled and the bloodwork is stable on Apoquel, there's no urgent reason to switch. Apoquel has a twelve-year post-market dataset. You know what you're working with. The case for switching is specific: your dog is showing neutrophil trends downward on Apoquel, recurring infections, or liver enzyme shifts, and your vet wants to try a JAK inhibitor with tighter selectivity. Numelvi's dataset is months deep, not years. The conversation with your vet is about weighing a proven track record against a selectivity advantage.
Join the Veta waitlist
When Veta opens for iOS, we'll tell you first. No spam, no roadmap emails. One note when the app is ready to download.
Rachel Howland, CVT (ret.), spent a decade in clinic: seven years in a mixed practice in upstate New York, then three on the internal-medicine floor at Angell Animal Medical Center in Boston. She left practice in 2017 and has written about small-animal health since. She does not diagnose or prescribe; she explains what your vet's records are telling you and what questions are fair to ask.